However, GLS inhibition was found to impair CD8 + T-cell activation in STK11-/LKB1-deficient lung cancer, and the use of CB-839 to inhibit CD8 + T-cell expansion negatively impacted tumor therapy [142]. Here, STK11 is linked to neoplasm.